These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 29560755)

  • 1. Nivolumab in squamous cell carcinoma of the head and neck.
    Specenier P
    Expert Rev Anticancer Ther; 2018 May; 18(5):409-420. PubMed ID: 29560755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
    Zargar M; McFarlane T; Chan KKW; Wong WWL
    Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
    Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
    Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma.
    Specenier P; Vermorken JB
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):901-915. PubMed ID: 29999437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
    Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML
    Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
    Matsuo M; Yasumatsu R; Masuda M; Toh S; Wakasaki T; Hashimoto K; Taura M; Uchi R; Nakagawa T
    Oral Oncol; 2020 Feb; 101():104525. PubMed ID: 31863963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
    Ferris RL; Licitra L; Fayette J; Even C; Blumenschein G; Harrington KJ; Guigay J; Vokes EE; Saba NF; Haddad R; Ramkumar S; Russell J; Brossart P; Tahara M; Colevas AD; Concha-Benavente F; Lynch M; Li L; Gillison ML
    Clin Cancer Res; 2019 Sep; 25(17):5221-5230. PubMed ID: 31239321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [First report on successful application of nivolumab in Hungary for the treatment of locally recurrent head and neck squamous cell carcinoma].
    Bellyei S; Bakó P; Orosz É; Molnár K; Remenár É; Mangel L
    Magy Onkol; 2018 Sep; 62(3):175-178. PubMed ID: 30256884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis.
    Pei R; Shi Y; Lv S; Dai T; Zhang F; Liu S; Wu B
    JAMA Netw Open; 2021 May; 4(5):e218065. PubMed ID: 33956130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma.
    Fushimi C; Okamoto I; Matsuki T; Masubuchi T; Okada T; Sato H; Tsukahara K; Kondo T; Yamashita T; Hanyu K; Omura GO; Takahashi H; Tada Y; Miura K
    Anticancer Res; 2020 Sep; 40(9):5277-5283. PubMed ID: 32878817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age.
    Saba NF; Blumenschein G; Guigay J; Licitra L; Fayette J; Harrington KJ; Kiyota N; Gillison ML; Ferris RL; Jayaprakash V; Li L; Brossart P
    Oral Oncol; 2019 Sep; 96():7-14. PubMed ID: 31422216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
    Haddad R; Concha-Benavente F; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Kasper S; Vokes EE; Worden F; Saba NF; Tahara M; Jayaprakash V; Lynch M; Li L; Gillison ML; Harrington KJ; Ferris RL
    Cancer; 2019 Sep; 125(18):3208-3218. PubMed ID: 31246283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
    Haddad R; Cohen EEW; Venkatachalam M; Young K; Singh P; Shaw JW; Korytowsky B; Abraham P; Harrington KJ
    J Med Econ; 2020 May; 23(5):442-447. PubMed ID: 31928375
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer.
    Suzuki C; Kiyota N; Imamura Y; Rikitake J; Sai S; Koyama T; Hyogo Y; Nagatani Y; Funakoshi Y; Toyoda M; Otsuki N; Nibu KI; Minami H
    Int J Clin Oncol; 2020 Jul; 25(7):1270-1277. PubMed ID: 32277393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
    Nadler E; Joo S; Boyd M; Black-Shinn J; Chirovsky D
    Future Oncol; 2019 Mar; 15(7):739-751. PubMed ID: 30511880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
    Saada-Bouzid E; Peyrade F; Guigay J
    Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040).
    Pai SI; Faivre S; Licitra L; Machiels JP; Vermorken JB; Bruzzi P; Gruenwald V; Giglio RE; Leemans CR; Seiwert TY; Soulieres D
    J Immunother Cancer; 2019 Apr; 7(1):96. PubMed ID: 30944020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial.
    Saba NF; Wong SJ; Nasti T; McCook-Veal AA; McDonald MW; Stokes WA; Anderson AM; Ekpenyong A; Rupji M; Abousaud M; Rudra S; Bates JE; Remick JS; Joshi NP; Woody NM; Awan M; Geiger JL; Shreenivas A; Samsa J; Ward MC; Schmitt NC; Patel MR; Higgins KA; Teng Y; Steuer CE; Shin DM; Liu Y; Ahmed R; Koyfman SA
    JAMA Oncol; 2024 Jul; 10(7):896-904. PubMed ID: 38780927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-based efficacy and safety of nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter retrospective study.
    Kondo T; Okamoto I; Sato H; Koyama N; Fushimi C; Okada T; Masubuchi T; Miura K; Matsuki T; Yamashita T; Omura G; Takahashi H; Tsukahara K
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):340-347. PubMed ID: 32573033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
    Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
    BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.